



9th Paris Hepatitis Conference

Paris, 11 January 2016

How to improve access to therapy? Around the World table

Massimo Colombo

Chairman Department of Liver, Kidney, Lung and Bone Marrow Units and Organ Transplant

Head Division of Gastroenterology and Hepatology

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

University of Milan

Milan, Italy

Financial Disclosures

Grant and research support: BMS, Gilead Science

Advisory committees: Merck, Roche, Novartis, Bayer, BMS, Gilead Science,
Tibotec, Vertex, Janssen Cilag, Achillion, Lundbeck, GSK,
GenSpera

Speaking and teaching: Tibotec, Roche, Novartis, Bayer, BMS, Gilead
Science, Vertex, Merck, Janssen

The Burden and Treatment of HCV in Italy

- Prevalence of HCV among the general population (0.6 – 1.2%), 300,000 identified
- National Plan against viral hepatitis (2015). Regional Registry of HCV therapy, not all
- Funding: 1 billion Euros 2015-2016
- NHS reimbursement of DAA: F3-F4, extrahepatic complications, organ transplanted
- 30,560 patients treated with DAA by NHS (January to December 2015)
- Future: scaling up taking advantage of increased competition between companies.
- Pending: screening of the general population & migrants